<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2dedbadd-050f-4a2e-9425-837bdef7632b"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use JAYPIRCA safely and effectively. See full prescribing information for JAYPIRCA.<br/>
      <br/>JAYPIRCA<sup>Â®</sup> (pirtobrutinib) tablets, for oral use <br/>Initial U.S. Approval: 2023
</title>
   <effectiveTime value="20250219"/>
   <setId root="bd551845-0878-49a4-860f-839b83f6b801"/>
   <versionNumber value="11"/>
   <author>
      <assignedEntity>
         <representedOrganization>
            <id extension="006421325" root="1.3.6.1.4.1.519.1"/>
            <name>Eli Lilly and Company</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="006421325" root="1.3.6.1.4.1.519.1"/>
                  <name>Eli Lilly and Company</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="f978b3d7-7bcf-4a04-9254-2a68feccb281"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20240820"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-6902" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>JAYPIRCA</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>pirtobrutinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="50" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JNA39I7ZVB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>pirtobrutinib</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JNA39I7ZVB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>pirtobrutinib</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36BGF0E889" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose acetate succinate 12070923 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>microcrystalline cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>croscarmellose sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>silicon dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>triacetin</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4AQJ3LG584" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE No. 2 Aluminum Lake</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-6902-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230127"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216059" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230127"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48353" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRIANGLE" xsi:type="CE">
                              <originalText>Arc-triangle Shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Lilly50;6902
</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-7026" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>JAYPIRCA</name>
                        <formCode code="C42897" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>pirtobrutinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JNA39I7ZVB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>pirtobrutinib</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="JNA39I7ZVB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>pirtobrutinib</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36BGF0E889" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose acetate succinate 12070923 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>microcrystalline cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>lactose monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>croscarmellose sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>silicon dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>magnesium stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hypromellose, unspecified</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>titanium dioxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>triacetin</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4AQJ3LG584" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE No. 2 Aluminum Lake</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="60"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-7026-60" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230127"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-7026-99" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230215"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA216059" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230127"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLUE" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="10" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic>
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Lilly100;7026
</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s0">
               <id root="4ca4119d-06bd-4892-8a6d-fe901d46d578"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240604"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="85.000%" align="left"/>
                           <col width="15.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top">Indications and Usage, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (<linkHtml href="#s2a">1.2</linkHtml>)
</td>
                                 <td align="right" valign="top">12/2023
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Warnings and Precautions, Hepatotoxicity, Including Drug-Induced Liver Injury (<linkHtml href="#s16a">5.6</linkHtml>)
</td>
                                 <td align="right" valign="top">06/2024
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="8ab9b1af-b7a7-48f0-a49b-6de599b8f203"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <effectiveTime value="20231220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>JAYPIRCA<sup>Â®</sup> is a kinase inhibitor indicated for the treatment of
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. (<linkHtml href="#s2">1.1</linkHtml>).<br/>This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
</item>
                           <item>Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. (<linkHtml href="#s2a">1.2</linkHtml>).<br/>This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s2">
                     <id root="9c4b6b87-178e-4698-96f0-6bed9e0162e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Mantle Cell Lymphoma
</title>
                     <text>
                        <paragraph>JAYPIRCA<sup>Â®</sup> is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
</paragraph>
                        <paragraph>This indication is approved under accelerated approval based on response rate <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s63">14.1</linkHtml>)].</content> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
</paragraph>
                     </text>
                     <effectiveTime value="20231220"/>
                  </section>
               </component>
               <component>
                  <section ID="s2a">
                     <id root="bc662fa8-22d9-42e6-b76b-fca65358fe0f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>JAYPIRCA is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
</paragraph>
                        <paragraph>This indication is approved under accelerated approval based on response rate <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s64">14.2</linkHtml>)].</content> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
</paragraph>
                     </text>
                     <effectiveTime value="20231220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="c142b8bd-d1c5-401b-a2d6-e45c42318991"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20230127"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Recommended dosage: 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets. (<linkHtml href="#s4">2.1</linkHtml>)
</item>
                           <item>Manage toxicity using treatment interruption, dosage reduction, or discontinuation. (<linkHtml href="#s5">2.2</linkHtml>)
</item>
                           <item>Reduce dose in patients with severe renal impairment. (<linkHtml href="#s6">2.3</linkHtml>, <linkHtml href="#s41">8.6</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s4">
                     <id root="aecbe24e-149a-4762-a334-ee7378f98b61"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosage
</title>
                     <text>
                        <paragraph>The recommended dosage of JAYPIRCA is 200 mg orally once daily until disease progression or unacceptable toxicity.
</paragraph>
                        <paragraph>Advise patients of the following:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Swallow tablets whole with water. Do not cut, crush, or chew tablets.
</item>
                           <item>Take JAYPIRCA at the same time each day. JAYPIRCA may be taken with or without food.
</item>
                           <item>If a dose of JAYPIRCA is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="5c6f0010-5b1b-4a12-91fc-7f3899c2912c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage Modifications for Adverse Reactions
</title>
                     <text>
                        <paragraph>Recommended dosage modifications of JAYPIRCA for adverse reactions are presented in <linkHtml href="#t1">Table 1
</linkHtml>
                           <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.1</linkHtml>, <linkHtml href="#s13">5.2</linkHtml>, <linkHtml href="#s14">5.3</linkHtml>, and <linkHtml href="#s15">5.4</linkHtml>)]</content>.
</paragraph>
                        <table ID="t1" width="100%">
                           <caption>Table 1: Recommended Dosage Modification of JAYPIRCA for Adverse Reactions
</caption>
                           <col width="31.933%" align="left"/>
                           <col width="23.567%" align="left"/>
                           <col width="44.500%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">Dose modification is not recommended for asymptomatic lymphocytosis. Asymptomatic lipase increase may not necessarily warrant dose modification.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> Evaluate the benefit-risk before resuming treatment at the same dose for a Grade 4 non-hematological toxicity.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Occurrences Requiring Dosage Modification</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Modification</content>
                                    <br/>(Starting Dosage: 200 mg once daily)
</td>
                              </tr>
                              <tr>
                                 <td rowspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Grade 3 or greater non-hematologic toxicity <sup>a</sup>
                                       </item>
                                       <item>Absolute neutrophil count &lt; 1 to 0.5 x 10<sup>9</sup>/L with fever and/or infection
</item>
                                       <item>Absolute neutrophil count &lt; 0.5 x 10<sup>9</sup>/L lasting 7 or more days
</item>
                                       <item>Platelet count &lt; 50 to 25 x 10<sup>9</sup>/L with bleeding
</item>
                                       <item>Platelet count &lt; 25 x 10<sup>9</sup>/L
</item>
                                    </list>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <content styleCode="bold">First occurrence</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at original dosage (200 mg once daily)<sup>a</sup>.
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <content styleCode="bold">Second occurrence</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 100 mg once daily.
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <content styleCode="bold">Third occurrence</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 50 mg once daily.
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">
                                    <content styleCode="bold">Fourth occurrence</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Discontinue JAYPIRCA.
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="5ae46831-ed37-4a20-83dc-6dda4644dd9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Modifications for Patients with Severe Renal Impairment
</title>
                     <text>
                        <paragraph>For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s42">8.7</linkHtml>), Clinical Pharmacology (<linkHtml href="#s48">12.3</linkHtml>)]</content>. No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).
</paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="ebdefebd-0401-4791-af19-ccaa60761614"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors
</title>
                     <text>
                        <paragraph>Avoid concomitant use of strong CYP3A inhibitors with JAYPIRCA <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s23">7.1</linkHtml>), Clinical PharmacologyÂ (<linkHtml href="#s48">12.3</linkHtml>)]</content>. If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the JAYPIRCA dose by 50Â mg. If the current dosage is 50 mg once daily, interrupt JAYPIRCA treatment for the duration of strong CYP3A inhibitor use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the JAYPIRCA dose that was taken prior to initiating the strong CYP3A inhibitor.
</paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
               <component>
                  <section ID="s8">
                     <id root="64048399-8574-406b-a2c4-e7c17adc2418"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modifications for Concomitant Use with CYP3A Inducers
</title>
                     <text>
                        <paragraph>Avoid concomitant use of strong or moderate CYP3A inducers with JAYPIRCA <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s23">7.1</linkHtml>), Clinical Pharmacology (<linkHtml href="#s48">12.3</linkHtml>)]</content>. If concomitant use with moderate CYP3A inducers is unavoidable and the current dosage of JAYPIRCA is 200 mg once daily, increase the dose to 300 mg. If the current dosage is 50 mg or 100 mg once daily, increase the dose by 50 mg.
</paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="ba922d7a-b4fa-48c3-977f-abe8cde66432"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Tablets:
</paragraph>
                  <paragraph>Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with âLilly 50â on one side and â6902â on the other side.
</paragraph>
                  <paragraph>Each 100 mg tablet is blue, round, film-coated, and debossed with âLilly 100â on one side and â7026â on the other side.
</paragraph>
               </text>
               <effectiveTime value="20231201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 50 mg, 100 mg (<linkHtml href="#s9">3</linkHtml>).
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="699b78fb-41c4-4776-ab6f-91c794da31d8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>None.
</paragraph>
               </text>
               <effectiveTime value="20231201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#s10">4</linkHtml>).
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="cebcc89d-8c9f-4978-81fb-05a2c7677bdb"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20240604"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Infections: Monitor for signs and symptoms of infection, evaluate promptly, and treat. (<linkHtml href="#s12">5.1</linkHtml>)
</item>
                           <item>Hemorrhage: Monitor for bleeding and manage appropriately. (<linkHtml href="#s13">5.2</linkHtml>)
</item>
                           <item>Cytopenias: Monitor complete blood counts during treatment. (<linkHtml href="#s14">5.3</linkHtml>)
</item>
                           <item>Cardiac Arrythmias: Monitor for symptoms of arrhythmias and manage appropriately. (<linkHtml href="#s15">5.4</linkHtml>)
</item>
                           <item>Second Primary Malignancies: Other malignancies have developed, including skin cancers and other carcinomas. Monitor and advise patients to use sun protection. (<linkHtml href="#s16">5.5</linkHtml>)
</item>
                           <item> Hepatotoxicity, Including Drug-Induced Liver Injury: Monitor hepatic function throughout treatment. (<linkHtml href="#s16a">5.6</linkHtml>)
</item>
                           <item> Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception. (<linkHtml href="#s17">5.7</linkHtml>, <linkHtml href="#s29">8.1</linkHtml>, <linkHtml href="#s35">8.3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s12">
                     <id root="12cf44ee-ffa8-4edc-89b0-92f46637d6e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Infections
</title>
                     <text>
                        <paragraph>Fatal and serious infections (including bacterial, viral, or fungal infections) and opportunistic infections have occurred in patients treated with JAYPIRCA. In the clinical trial, Grade 3 or higher infections occurred in 24% of 593 patients, most commonly pneumonia (14%), with fatal infections occurring in 4.4% of patients. Sepsis occurred in 6% of patients and febrile neutropenia in 4%. In patients with CLL/SLL, Grade 3 or higher infections occurred in 32% of patients, with fatal infections occurring in 8%. Opportunistic infections after treatment with JAYPIRCA have included, but are not limited to, <content styleCode="italics">Pneumocystis jirovecii</content> pneumonia and fungal infection <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s19">6.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients who are at increased risk for infections, including opportunistic infections. Monitor patients for signs and symptoms of infection, evaluate promptly, and treat appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <content styleCode="italics">[seeÂ Dosage and Administration (<linkHtml href="#s5">2.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20231201"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="82c26946-a71f-4a1b-b8cc-d3eaaf8b4814"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hemorrhage
</title>
                     <text>
                        <paragraph>Fatal and serious hemorrhage has occurred with JAYPIRCA. Major hemorrhage (defined as Grade 3 or higher bleeding or any central nervous system bleeding) occurred in 3% of 593 patients treated with JAYPIRCA, including gastrointestinal hemorrhage; fatal hemorrhage occurred in 0.3% of patients.Â Bleeding of any grade, excluding bruising and petechiae, occurred in 17% of patients <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s19">6.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Major hemorrhage occurred in 2.3% of patients taking JAYPIRCA without antithrombotic agents and 0.7% of patients taking JAYPIRCA with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with JAYPIRCA. Monitor patients for signs of bleeding. Based on severity of bleeding, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s5">2.2</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Consider the benefit-risk of withholding JAYPIRCA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.
</paragraph>
                     </text>
                     <effectiveTime value="20231201"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="c533a38b-732b-4433-be5b-cb58b89146a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Cytopenias
</title>
                     <text>
                        <paragraph>JAYPIRCA can cause cytopenias, including neutropenia, thrombocytopenia, and anemia.
</paragraph>
                        <paragraph>In the clinical trial, Grade 3 or 4 cytopenias, including decreased neutrophils (26%), decreased platelets (12%), and decreased hemoglobin (12%) developed in patients treated with JAYPIRCA. Grade 4 decreased neutrophils developed in 14% of patients and Grade 4 decreased platelets developed in 6% of patients <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s19">6.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Monitor complete blood counts regularly during treatment. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s5">2.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231201"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="0c6dae64-3bb7-4102-b31f-8db1aa564293"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Cardiac Arrhythmias
</title>
                     <text>
                        <paragraph>Cardiac arrhythmias, including atrial fibrillation and atrial flutter, were reported in recipients of JAYPIRCA. Atrial fibrillation or flutter were reported in 3.2%Â of patients, with Grade 3 or 4 atrial fibrillation or flutter reported in 1.5% of 593 patients in the clinical trial <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s19">6.1</linkHtml>)]</content>. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred in 0.5% of patients. Patients with cardiac risk factors, such as hypertension, or previous arrhythmias may be at increased risk.
</paragraph>
                        <paragraph>Monitor for signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea) and manage appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s5">2.2</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20231201"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="28e03062-9ea8-4b9a-9ca1-cb644bb757e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Second Primary Malignancies
</title>
                     <text>
                        <paragraph>Second primary malignancies, including non-skin carcinomas, developed in 9% of 593 patients treated with JAYPIRCA monotherapy. The most frequent malignancy was non-melanoma skin cancer, reported in 4.6% of 593 patients. Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor patients for the development of second primary malignancies.
</paragraph>
                     </text>
                     <effectiveTime value="20231201"/>
                  </section>
               </component>
               <component>
                  <section ID="s16a">
                     <id root="66b7f25c-de55-4f57-9659-bfcf776ab62f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange"/>5.6 Hepatotoxicity, Including Drug-Induced Liver Injury
</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange"/>Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including JAYPIRCA.
</paragraph>
                        <paragraph>
                           <content styleCode="xmChange"/>Evaluate bilirubin and transaminases at baseline and throughout treatment with JAYPIRCA. For patients who develop abnormal liver tests after JAYPIRCA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold JAYPIRCA. Upon confirmation of DILI, discontinue JAYPIRCA.
</paragraph>
                     </text>
                     <effectiveTime value="20240604"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="a2fecf99-e5b2-42b8-9e65-60d5a3f6856e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Embryo-Fetal Toxicity
</title>
                     <text>
                        <paragraph>Based on findings in animals, JAYPIRCA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of pirtobrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended dose of 200 mg once daily. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s29">8.1</linkHtml>, <linkHtml href="#s35">8.3</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240604"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s18">
               <id root="a1920f77-262e-409c-a185-4052ac51e4ee"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Infections <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.1</linkHtml>)]</content>
                     </item>
                     <item>Hemorrhage <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.2</linkHtml>)]</content>
                     </item>
                     <item>Cytopenias <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.3</linkHtml>)]</content>
                     </item>
                     <item>Atrial Fibrillation and Atrial Flutter <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.4</linkHtml>)]</content>
                     </item>
                     <item>Second Primary Malignancies <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.5</linkHtml>)]</content>
                     </item>
                     <item>Hepatotoxicity, including DILI <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16a">5.6</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20240604"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (â¥ 20%) are fatigue, musculoskeletal pain, diarrhea, COVID-19, bruising, and cough. Grade 3 or 4 laboratory abnormalities (â¥ 10%) are neutrophil count decreased, platelet count decreased, hemoglobin decreased, and lymphocyte count decreased. (<linkHtml href="#s19">6.1</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s19">
                     <id root="36d8b1c5-f945-4d6a-b074-fedd58f51fbf"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population.
</paragraph>
                        <paragraph>The data in the WARNINGS AND PRECAUTIONS reflect exposure to JAYPIRCA as a single-agent, administered at 200Â mg once daily in 593 patients with hematologic malignancies in the BRUIN study. Among these 593 patients, the median duration of exposure was 10 months, 62% were exposed for at least 6 months and 45% were exposed for at least one year.
</paragraph>
                        <paragraph>In this pooled safety population, the most common (â¥ 20%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (46%), decreased hemoglobin (39%), fatigue (32%), decreased lymphocyte count (31%), musculoskeletal pain (30%), decreased platelet count (29%), diarrhea (24%), COVID-19 (22%), bruising (21%), and cough (20%).
</paragraph>
                     </text>
                     <effectiveTime value="20231201"/>
                     <component>
                        <section ID="s19a">
                           <id root="1f711cda-a222-461e-aaae-9cfb010c306e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mantle Cell Lymphoma</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231201"/>
                           <component>
                              <section ID="s19b">
                                 <id root="a006b6cb-7735-4d43-a207-58b26b2f154c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">BRUIN</content>
                                    </paragraph>
                                    <paragraph>The safety of JAYPIRCA was evaluated in the BRUIN trial in patients with MCL who received a prior BTK inhibitor <content styleCode="italics">[seeÂ Clinical Studies (<linkHtml href="#s63">14.1</linkHtml>
                                       </content>)<content styleCode="italics">]</content>. The trial required a platelet count â¥ 50 x 10<sup>9</sup>/L, absolute neutrophil count â¥ 0.75 x 10<sup>9</sup>/L, hepatic transaminases â¤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding or grade â¥ 3 arrhythmia with a prior BTK inhibitor, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.
</paragraph>
                                    <paragraph>Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (n = 128); 36%Â were exposed for 6 months or longer and 10% were exposed for at least one year. The median number of prior therapies was 3 (range: 1-9). The median age was 71 years (range: 46 to 88 years) and 80% of patients were male. Race was reported for all patients; 78% were White, 14% were Asian, 2.3% were Black, and 2.3% were Hispanic or Latino.
</paragraph>
                                    <paragraph>Serious adverse reactions occurred in 38% of patients who received JAYPIRCA. Serious adverse reactions that occurred in â¥ 2% of patients were pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 7%Â of patients, most commonly due to infections (4.7%) including COVID-19 (3.1% of all patients).
</paragraph>
                                    <paragraph>Adverse reactions led to dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions that resulted in dosage modification in &gt; 5% of patients included pneumonia and neutropenia. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in &gt; 1% of patients included pneumonia.
</paragraph>
                                    <paragraph>The most common adverse reactions (â¥ 15%), excluding laboratory terms, were fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.
</paragraph>
                                    <paragraph>
                                       <linkHtml href="#t2">Table 2</linkHtml> summarizes select adverse reactions in BRUIN.
</paragraph>
                                    <table ID="t2" width="100%">
                                       <caption>Table 2: Adverse Reactions (â¥ 10%) in Patients with MCL Who Received JAYPIRCA
</caption>
                                       <col width="37.467%" align="left"/>
                                       <col width="31.267%" align="left"/>
                                       <col width="31.267%" align="left"/>
                                       <thead>
                                          <tr>
                                             <th rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                             <th colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">JAYPIRCA</content>
                                                <br/>
                                                <content styleCode="bold">200 mg once daily</content>
                                             </th>
                                          </tr>
                                          <tr>
                                             <th colspan="2" align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">N = 128</content>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> Each term listed includes other related terms.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> includes 1 fatality from COVID-19 pneumonia
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> includes 1 fatality from hemorrhage
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="bottom" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Adverse Reactions
</content>
                                                <content styleCode="bold">
                                                   <sup>a</sup>
                                                </content>
                                             </td>
                                             <td align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">All Grades (%)</content>
                                             </td>
                                             <td align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Grade 3-4 (%)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">General Disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fatigue
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">29
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Edema
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">18
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fever
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Musculoskeletal pain
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">27
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.9
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Arthritis or arthralgia
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.8
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Gastrointestinal Disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Constipation
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Abdominal pain
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Respiratory, thoracic, and mediastinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dyspnea
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">17
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.3
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Cough
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Injury</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Bruising
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">16
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Infections</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pneumonia
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">16 <sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Upper respiratory tract infections
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.8
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Nervous system disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Peripheral neuropathy
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dizziness
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Skin and subcutaneous disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Rash
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Vascular disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hemorrhage
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">11 <sup>c</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.1
</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Clinically relevant adverse reactions in &lt; 10% include vision changes, memory changes, headache, urinary tract infection, herpesvirus infection, and tumor lysis syndrome.
</paragraph>
                                    <paragraph>
                                       <linkHtml href="#t3">Table 3</linkHtml> summarizes laboratory abnormalities in BRUIN.
</paragraph>
                                    <table ID="t3" width="100%">
                                       <caption>Table 3: Select Laboratory Abnormalities (â¥ 10%) That Worsened from Baseline in Patients with MCL Who Received JAYPIRCA
</caption>
                                       <col width="37.467%" align="left"/>
                                       <col width="31.267%" align="left"/>
                                       <col width="31.267%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup>  The denominator used to calculate the rate varied from 90 to 127 based on the number of patients with a baseline value and at least one post-treatment value.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                                <content styleCode="bold">Laboratory Abnormality</content>
                                             </td>
                                             <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">JAYPIRCA
</content>
                                                <content styleCode="bold">
                                                   <sup>a</sup>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">200 mg once daily</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">All Grades (%)</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Grade 3 or 4 (%)</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hemoglobin decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">42
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">9
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Platelet count decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">39
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Neutrophil count decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">36
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">16
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Lymphocyte count decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">32
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">15
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Chemistry</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Creatinine increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">30
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Calcium decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">AST increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">17
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Potassium decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Sodium decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Lipase increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">4.4
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Alkaline phosphatase increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">-
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">ALT increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Potassium increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.8
</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Grade 4 laboratory abnormalities in &gt; 5% of patients included neutrophils decreased (10%), platelets decreased (7%), and lymphocytes decreased (6%).
</paragraph>
                                    <paragraph>
                                       <content styleCode="underline">Lymphocytosis</content>: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased â¥ 50% from baseline and a post-baseline value â¥ 5,000/Î¼L) occurred in 34% of MCL patients in BRUIN. The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 2.1 weeks, and the median duration was 11 weeks.
</paragraph>
                                 </text>
                                 <effectiveTime value="20231201"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s20">
                           <id root="ce1a2710-c073-4498-9054-4871cb401e6c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20231201"/>
                           <component>
                              <section ID="s20a">
                                 <id root="cc4101eb-a778-4c09-afd6-f056760795c7"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">BRUIN</content>
                                    </paragraph>
                                    <paragraph>The safety of JAYPIRCA was evaluated in the BRUIN trial in 110 patients with CLL/SLL, with 98% receiving at least two prior lines of systemic therapy including a BTK inhibitor and a BCL-2 inhibitor <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s64">14.2</linkHtml>
                                       </content>)<content styleCode="italics">]</content>. The trial required a platelet count â¥ 50 x 10<sup>9</sup>/L, absolute neutrophil count â¥ 0.75 x 10<sup>9</sup>/L, hepatic transaminases â¤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding, uncontrolled or symptomatic arrhythmias, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.
</paragraph>
                                    <paragraph>Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (N = 110); 60%Â were exposed for at least 1 year and 14% were exposed for at least two years. The median age was 68 years (range: 41 to 88 years) and 67% of patients were male. Race was reported in 110 (100%) patients; of these patients, 89% were White, 4.5% were Black, 1.8% were Asian, and 1.8% were Hispanic or Latino. The median number of prior therapies was 5 (range: 1-11).
</paragraph>
                                    <paragraph>Serious adverse reactions occurred in 56% of patients who received JAYPIRCA. Serious adverse reactions that occurred in â¥ 5% of patients were pneumonia (18%), COVID-19 (9%), sepsis (7%), and febrile neutropenia (7%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 11% of patients, most commonly due to infections (10%), including sepsis (5%) and COVID-19 (2.7%).
</paragraph>
                                    <paragraph>Adverse reactions led to dose reductions in 3.6%, treatment interruption in 42%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions which resulted in dose reductions of JAYPIRCA in &gt; 1% of patients included neutropenia. Adverse reactions which resulted in treatment interruptions of JAYPIRCA in &gt; 5% of patients included pneumonia, neutropenia, febrile neutropenia, and COVID-19. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in &gt; 1% of patients included second primary malignancy, COVID-19, and sepsis.
</paragraph>
                                    <paragraph>The most common adverse reactions (â¥ 20%), excluding laboratory terms, were fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, dyspnea, hemorrhage, edema, nausea, pyrexia, and headache. <linkHtml href="#t4">Table 4</linkHtml> summarizes select adverse reactions for patients treated on BRUIN.
</paragraph>
                                    <table ID="t4" width="100%">
                                       <caption>Table 4: Adverse Reactions (â¥ 10%) in Patients with CLL/SLL Who Received JAYPIRCA
</caption>
                                       <col width="37.467%" align="left"/>
                                       <col width="31.267%" align="left"/>
                                       <col width="31.267%" align="left"/>
                                       <thead>
                                          <tr>
                                             <th rowspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                             <th colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">JAYPIRCA</content>
                                                <br/>
                                                <content styleCode="bold">200 mg once daily</content>
                                             </th>
                                          </tr>
                                          <tr>
                                             <th colspan="2" align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">N = 110</content>
                                             </th>
                                          </tr>
                                          <tr>
                                             <th align="left" valign="bottom" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Adverse Reactions
</content>
                                                <content styleCode="bold">
                                                   <sup>a</sup>
                                                </content>
                                             </th>
                                             <th align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">All Grades (%)</content>
                                             </th>
                                             <th align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Grade 3-4 (%)</content>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> Each term listed includes other related terms.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> Includes COVID-19 pneumonia. Includes 1 fatalities from COVID-19 and 2 fatalities from COVID-19 pneumonia
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> Includes COVID-19 pneumonia. Includes 2 fatalities from COVID-19 pneumonia and 1 fatality from pneumonia
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>d</sup> Includes preferred terms hemorrhage, intracranial hemorrhage, and gastrointestinal hemorrhage
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>e</sup> Includes preferred terms memory impairment, confusional state, encephalopathy, mental status changes
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>f</sup> Includes preferred terms second primary malignancy and nonmelanoma skin cancers. 1 fatality from metastatic malignant melanoma
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>g</sup> Includes preferred terms renal failure, chronic kidney disease, acute kidney injury
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>h</sup>Includes preferred terms supraventricular tachycardia, sinus tachycardia, atrial fibrillation
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">General Disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fatigue
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">36
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Edema
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pyrexia
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">20
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Injury</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Bruising
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">36
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Fall
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.9
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Respiratory, thoracic, and mediastinal disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Cough
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">33
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dyspnea
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">22
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Mucositis
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.9
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Musculoskeletal pain
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">32
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.9
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Arthritis or arthralgia
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.8
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Infections</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">COVID-19
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">28<sup>b</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pneumonia
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">27<sup>c</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">16
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Upper respiratory tract infections
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Respiratory tract infection
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">11
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.8
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Gastrointestinal Disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">26
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Abdominal pain
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">25
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Constipation
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Vascular disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hemorrhage
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">22<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hypertension
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Nervous system disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">20
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.9
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Peripheral neuropathy
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">16
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">3.6
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dizziness
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">15
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Neurological changes
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">12<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Skin and subcutaneous disorders</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Rash
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0.9
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Psychiatric disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Insomnia
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">14
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Neoplasms benign, malignant and unspecified</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Second primary malignancy
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">13<sup>f</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.7
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Renal and urinary disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Renal insufficiency
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">12<sup>g</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">6
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Metabolism and nutrition disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased appetite
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">12
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Cardiac disorders</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Supraventricular tachycardia
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">10<sup>h</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">5
</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Clinically relevant adverse reactions in &lt; 10% include vision changes, lower respiratory tract infection, urinary tract infection, herpesvirus infection, and tumor lysis syndrome.
</paragraph>
                                    <paragraph>
                                       <linkHtml href="#t5">Table 5</linkHtml> summarizes laboratory abnormalities in BRUIN.
</paragraph>
                                    <table ID="t5" width="100%">
                                       <caption>Table 5: Select Laboratory Abnormalities (â¥ 20%) That Worsened from Baseline in Patients with CLL/SLL Who Received JAYPIRCA
</caption>
                                       <col width="37.433%" align="left"/>
                                       <col width="31.200%" align="left"/>
                                       <col width="31.367%" align="left"/>
                                       <thead>
                                          <tr>
                                             <th rowspan="2" align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule">
                                                <content styleCode="bold">Laboratory Abnormality</content>
                                             </th>
                                             <th colspan="2" align="center" valign="bottom" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">JAYPIRCA
</content>
                                                <content styleCode="bold">
                                                   <sup>a</sup>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">200 mg once daily<br/>
                                                </content>
                                             </th>
                                          </tr>
                                          <tr>
                                             <th align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">All Grades (%)</content>
                                             </th>
                                             <th align="center" valign="bottom" styleCode="Botrule Rrule">
                                                <content styleCode="bold">Grade 3 or 4 (%)</content>
                                             </th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup>  The denominator used to calculate the rate varied from 83 to 108 based on the number of patients with a baseline value and at least one post-treatment value.
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Hematology</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Neutrophil count decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">63
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">45
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Hemoglobin decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">48
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">19
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Platelet count decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">30
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">15
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Lymphocyte count decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                                <content styleCode="bold">Chemistry</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                             <td align="center" valign="top" styleCode="Botrule Rrule"/>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Calcium decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">40
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Sodium decreased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">30
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">ALT increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">2.8
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">AST increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">1.9
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Creatinine increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Lipase increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Alkaline phosphatase increased
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">21
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">0
</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Grade 4 laboratory abnormalities in &gt; 5% of patients included neutrophils decreased (23%).
</paragraph>
                                 </text>
                                 <effectiveTime value="20231201"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s21">
                           <id root="555a4917-8c73-439a-8f7c-0b76503a40eb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">**Lymphocytosis</content>: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased â¥ 50% from baseline and a post-baseline value â¥ 5,000/Î¼L) occurred in 64% of CLL/SLL patients in BRUIN. The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 1.1 weeks, and the median duration was 19 weeks.
</paragraph>
                           </text>
                           <effectiveTime value="20231201"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s22">
               <id root="44d72d16-5cbf-44a2-8487-4eaec0ce7604"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <effectiveTime value="20230127"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (<linkHtml href="#s7">2.4</linkHtml>, <linkHtml href="#s23">7.1</linkHtml>)
</item>
                           <item>Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (<linkHtml href="#s8">2.5</linkHtml>, <linkHtml href="#s23">7.1</linkHtml>)
</item>
                           <item>Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (<linkHtml href="#s26">7.2</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s23">
                     <id root="963d727d-e1d4-4ca7-9323-8bed3fe421a6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on JAYPIRCA
</title>
                     <effectiveTime value="20230127"/>
                     <component>
                        <section ID="s24">
                           <id root="63f89187-eb6b-4db6-9719-ac88ae0bf177"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong CYP3A Inhibitors</content>
                              </paragraph>
                              <paragraph>Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s48">12.3</linkHtml>)]</content>, which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant use of strong CYP3A inhibitors is unavoidable, reduce the JAYPIRCA dosage <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s7">2.4</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s25">
                           <id root="5f18a070-4ad3-4c2b-9215-35b713eaac6a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Strong or Moderate CYP3A Inducers</content>
                              </paragraph>
                              <paragraph>Concomitant use of JAYPIRCA with a strong or moderate CYP3A inducer decreased pirtobrutinib systemic exposure <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s48">12.3</linkHtml>)]</content>, which may reduce JAYPIRCA efficacy. Avoid concomitant use of JAYPIRCA with strong or moderate CYP3A inducers. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dosage <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s8">2.5</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s26">
                     <id root="da70b313-f2ea-41e8-bb18-22772caee05b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of JAYPIRCA on Other Drugs
</title>
                     <effectiveTime value="20230127"/>
                     <component>
                        <section ID="s27">
                           <id root="d0c1b630-ff38-4533-977b-263704659b45"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates</content>
                              </paragraph>
                              <paragraph>JAYPIRCA is a P-gp inhibitor, a moderate CYP2C8 and BCRP inhibitor, and a weak CYP2C19 and CYP3A inhibitor. Concomitant use of JAYPIRCA with sensitive P-gp, CYP2C8, BCRP, CYP2C19, or CYP3A substrates increased their plasma concentrations <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s48">12.3</linkHtml>)],</content> which may increase the risk of adverse reactions related to these substrates for drugs which are sensitive to minimal concentration changes. Follow recommendations for sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP substrates provided in their approved product labeling.
</paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s28">
               <id root="7f7801b7-4ebb-44b5-9045-169b63022bd9"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20231201"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lactation: Advise not to breastfeed (<linkHtml href="#s33">8.2</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s29">
                     <id root="7c4133eb-d6d1-4ffe-b125-9e6934c1be64"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20231201"/>
                     <component>
                        <section ID="s30">
                           <id root="b29fbd7a-e257-4c6c-914d-92e06fd21d8d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman. There are no available data on JAYPIRCA use in pregnant women to evaluate for a drug-associated risk. In an animal reproduction study, administration of pirtobrutinib to pregnant rats during organogenesis resulted in adverse developmental outcomes, including structural abnormalities, altered fetal growth, and embryo-fetal mortality, at maternal exposures approximately 3-times those in patients at the recommended daily dose of 200 mg (see Data). Advise pregnant women of the potential risk to a fetus.
</paragraph>
                              <paragraph>The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.
</paragraph>
                           </text>
                           <effectiveTime value="20231201"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s31">
                           <id root="13fcef7d-6380-48e5-a7fb-9b16a94132ad"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                           <component>
                              <section ID="s32">
                                 <id root="b1ceb8ad-89ff-43f0-9861-dce9917b2a88"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal development study in rats, pregnant animals were administered oral doses of pirtobrutinib at up to 500Â mg/kg twice daily during the period of organogenesis. Doses â¥ 375 mg/kg twice daily caused decreased fetal body weights and increased incidence of malformations and variations in the urinary tract (including absent or abnormal ureters and kidneys), reproductive tract (malpositioned ovaries and misshapen uterus), and bone (misshapen sternebrae). At 500Â mg/kg twice daily, total resorption was observed. At 375 mg/kg twice daily in rats, the maternal systemic exposures (AUC) were approximately 3 times the human exposure at 200 mg once daily.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230127"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s33">
                     <id root="90206b0c-bb85-4d5f-b266-e04391ebd6a3"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20230127"/>
                     <component>
                        <section ID="s34">
                           <id root="3a7ad1bb-3843-4e2d-84b2-46a41ec5420a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of pirtobrutinib in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with JAYPIRCA and for one week after the last dose.
</paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s35">
                     <id root="eee42da7-4b38-4737-ba46-13406122030e"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential
</title>
                     <text>
                        <paragraph>Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s29">8.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                     <component>
                        <section ID="s36">
                           <id root="f6095f39-e246-4928-a57a-109b18f88861"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating JAYPIRCA.
</paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s37">
                           <id root="de4984f6-0ab2-4cf4-8444-3f81b202976f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                           <component>
                              <section ID="s38">
                                 <id root="d1316fa5-5eb2-401e-910a-fe775647c051"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230127"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s39">
                     <id root="2add43c7-c068-4c3d-a9ef-bf2dc842bea7"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>Safety and effectiveness of JAYPIRCA have not been established in pediatric patients.
</paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
               <component>
                  <section ID="s40">
                     <id root="575ce4e9-928c-482b-b752-750199568b83"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>Of the patients with MCL who received the 200 mg dose of JAYPIRCA in BRUIN, 93 (78%) were 65 years of age and older and 39 (33%) were 75 years and older <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s63">14.1</linkHtml>)]</content>. Clinical studies of JAYPIRCA did not include sufficient numbers of patients with MCL who were less than 65 years of age to determine whether older patients respond differently from younger adult patients. Of the patients with CLL/SLL who received the 200 mg once daily dose of JAYPIRCA in BRUIN, 68 (63%) were 65 years of age and older and 21 (19%) were 75 years and older <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s64">14.2</linkHtml>)]</content>. No overall differences in effectiveness were observed between younger and older patients.
</paragraph>
                        <paragraph>In the pooled safety population in patients with hematologic malignancies, 401 (68%) were 65 years of age and older, while 154 (26%) were 75 years of age and older. Patients aged 65 years and older experienced higher rates of Grade 3 and higher adverse reactions and serious adverse reactions compared to patients who were less than 65 years of age.
</paragraph>
                     </text>
                     <effectiveTime value="20231201"/>
                  </section>
               </component>
               <component>
                  <section ID="s41">
                     <id root="842173b1-2a1d-4464-8aff-5a5a9abc4fb8"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment
</title>
                     <text>
                        <paragraph>Severe renal impairment (eGFR15-29 mL/min) increases pirtobrutinib exposure <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s48">12.3</linkHtml>)]</content>. Reduce the JAYPIRCA dosage in patients with severe renal impairment <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s6">2.3</linkHtml>)]</content>. No dosage adjustment of JAYPIRCA is recommended in patients with mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment.
</paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
               <component>
                  <section ID="s42">
                     <id root="8a7a122c-e58e-43ba-b0a4-81562317b82d"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Hepatic Impairment
</title>
                     <text>
                        <paragraph>No dosage adjustment of JAYPIRCA is recommended in patients with mild hepatic impairment (total bilirubin â¤ upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 Ã ULN and any AST), moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 Ã ULN and any AST), or severe hepatic impairment (total bilirubin &gt; 3 Ã ULN and any AST) <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s48">12.3</linkHtml>
                           </content>)<content styleCode="italics">].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s43">
               <id root="7bf10532-fb9b-428a-b512-6f88fd156132"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>Pirtobrutinib is a kinase inhibitor. It is an orally available, small molecule ATP-competitive inhibitor of BTK. The active pharmaceutical ingredient is pirtobrutinib with the molecular formula C<sub>22</sub>H<sub>21</sub>F<sub>4</sub>N<sub>5</sub>O<sub>3</sub> and a molecular weight of 479.44 g/mol. The chemical name for pirtobrutinib is 5-amino-3-{4-[(5-fluoro-2-methoxybenzamido)methyl]phenyl}-1-[(2<content styleCode="italics">S</content>)-1,1,1-trifluoropropan-2-yl]-1<content styleCode="italics">H</content>-pyrazole-4-carboxamide.
</paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  </paragraph>
                  <paragraph>Pirtobrutinib is a white to practically white to yellow to brown solid. The aqueous solubility of pirtobrutinib is considered practically insoluble, or insoluble, across the pH 1 to pH 7 range.
</paragraph>
                  <paragraph>Pirtobrutinib tablets are supplied as 50 mg or 100 mg film-coated, debossed tablets for oral administration. Each tablet contains inactive ingredients of croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose and silicon dioxide. The tablet film coating material contains FD&amp;C Blue #2, hypromellose, titanium dioxide and triacetin.
</paragraph>
               </text>
               <effectiveTime value="20230127"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Chemical Structure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jaypirca-uspi-chem-str-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s44">
               <id root="a02294ac-c0c8-49db-b401-9a37dcf5d114"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20231201"/>
               <component>
                  <section ID="s45">
                     <id root="38e045f5-8c10-47e1-9959-fd4deef3e7b4"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of action
</title>
                     <text>
                        <paragraph>Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.
</paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
               <component>
                  <section ID="s46">
                     <id root="599d4d9f-3b56-4ba1-a75e-7f160a6d4cc1"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <text>
                        <paragraph>At the recommended dosage of 200 mg once daily, pirtobrutinib trough concentrations exceeded the BTK IC<sub>96</sub>. BTK occupancy is maintained throughout the dosing interval, regardless of the intrinsic rate of BTK turnover.
</paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                     <component>
                        <section ID="s47">
                           <id root="5b516694-ef17-4722-8e6f-76b36df93fe7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>The effect of a single 900 mg dose of pirtobrutinib (equivalent to approximately 2 times higher than the concentrations achieved at steady state at the recommended dosage of 200 mg once daily) on the QTc interval was evaluated in a placebo-controlled and positive-controlled study in 30 healthy subjects. Pirtobrutinib had no clinically meaningful effect on the change in QTcF interval (i.e., &gt; 10 ms) and there was no relationship between pirtobrutinib exposure and change in QTc interval.
</paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s48">
                     <id root="a7cadd80-7d70-48f1-8e94-3a0dae5bf7f0"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <text>
                        <paragraph>The pharmacokinetics of pirtobrutinib were characterized in healthy subjects and in patients with cancer. Pirtobrutinib exposure (AUC) and C<sub>max</sub> increases proportionally following single oral doses ranging from 300 mg to 800 mg (1.5 to 4Â times the approved recommended dosage) and once daily doses ranging from 25 â 300 mg (0.125 to 1.5 times the recommended dosage). Steady state was achieved within 5 days of once daily dosing, and the mean (CV%) accumulation ratio was 1.63 (26.7%) based on AUC after administration of 200 mg dosages.
</paragraph>
                        <paragraph>Following administration of the recommended dosage, the geometric mean (CV%) steady-state AUC and C<sub>max</sub> of pirtobrutinib were 90300 h*ng/mL (40%) and 6380 ng/mL (26%), respectively. The geometric mean (CV%) AUC<sub>0-24</sub> and C<sub>max</sub> of pirtobrutinib on Cycle 1 Day 8 were 81800 h*ng/mL (66.6%) and 3670 ng/mL (89.5%), respectively.
</paragraph>
                     </text>
                     <effectiveTime value="20231201"/>
                     <component>
                        <section ID="s49">
                           <id root="0d9b56eb-c688-4dbe-9f2b-9e6dde7972d8"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The absolute bioavailability of pirtobrutinib after a single oral 200 mg dose is 85.5% (range 75.9% to 90.9%). The median time (range) to reach peak plasma concentration (t<sub>max</sub>) is approximately 2 hours (0.833 to 4.15 hours).
</paragraph>
                           </text>
                           <effectiveTime value="20231201"/>
                           <component>
                              <section ID="s50">
                                 <id root="9fa47ef1-4751-4698-8b91-5e0fbd4c1e13"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>No clinically significant differences in the pharmacokinetics of pirtobrutinib were observed following administration of a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) to healthy subjects. A high-fat meal decreased the C<sub>max</sub> of pirtobrutinib by 23% and delayed t<sub>max</sub> by 1 hour. There was no effect on pirtobrutinib AUC.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230127"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s51">
                           <id root="b679e27a-1e60-469e-bc09-a7a65595c447"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The mean apparent central volume of distribution of pirtobrutinib is 34.1 L. Human protein binding of pirtobrutinib is 96%Â and is independent of concentration in vitro. Mean blood-to-plasma ratio is 0.79.
</paragraph>
                           </text>
                           <effectiveTime value="20231201"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s52">
                           <id root="03aced8c-4f18-4a1d-ab25-26fe6d18f638"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The effective half-life of pirtobrutinib is approximately 19 hours and the mean (CV%) apparent clearance is 2.05 L/h (37.2%).
</paragraph>
                           </text>
                           <effectiveTime value="20231201"/>
                           <component>
                              <section ID="s53">
                                 <id root="6cbe383f-6957-49b9-9624-c3552c7314a4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Pirtobrutinib is primarily metabolized by CYP3A4 and direct glucuronidation by UGT1A8 and UGT1A9, in vitro.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230127"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s54">
                                 <id root="46aa9b54-952d-492b-8892-9c08b8ed4d8a"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Following a single radiolabeled dose of pirtobrutinib 200 mg to healthy subjects, 37% of the dose was recovered in feces (18% unchanged) and 57% in urine (10% unchanged).
</paragraph>
                                 </text>
                                 <effectiveTime value="20230127"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s55">
                           <id root="8fc0e5b0-edaf-4ea5-a5a6-461de37b8035"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>There were no clinically significant differences in the pharmacokinetics of pirtobrutinib based on age (range 22Â âÂ 95Â years), sex, race/ethnicity (White 84%, Asian 7%), body weight (range 35.7 â 152 kg), mild (total bilirubin â¤ upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 Ã ULN and any AST), moderate (total bilirubin &gt; 1.5 to 3 Ã ULN and any AST), or severe (total bilirubin &gt; 3 Ã ULN and any AST) hepatic impairment. The effect of other races/ethnicities on the pharmacokinetics of pirtobrutinib is unknown.
</paragraph>
                           </text>
                           <effectiveTime value="20231201"/>
                           <component>
                              <section ID="s56">
                                 <id root="cdf51e30-f5e0-4eea-96f7-71debe0cdd19"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Following a single 200 mg oral dose, the AUC of pirtobrutinib in subjects with severe renal impairment (eGFR 15-29Â mL/min) increased by 62% and mean unbound AUC increased by 68% compared to healthy subjects with normal renal function. There were no clinically significant differences in the pharmacokinetics of pirtobrutinib in subjects with mild (eGFR 60-89 mL/min) or moderate renal impairment (eGFR 30-59 mL/min). The effect of renal impairment requiring dialysis on the pharmacokinetics of pirtobrutinib is unknown.
</paragraph>
                                 </text>
                                 <effectiveTime value="20231201"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s57">
                           <id root="422f80da-fbb8-4b94-9324-51c737d6d3c7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230127"/>
                           <component>
                              <section ID="s58">
                                 <id root="54a3372e-2675-4139-8605-b99c6465e698"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Clinical Studies and Model-Informed Approaches</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Strong CYP3A Inhibitors:</content> Co-administration of a single 200 mg dose of pirtobrutinib with itraconazole (strong CYP3A inhibitor) increased AUC of pirtobrutinib by 49%.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Moderate CYP3A Inhibitors:</content> Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the AUC of pirtobrutinib by 30% and 20%, respectively.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Strong CYP3A inducers:</content> Coadministration of a single 200 mg dose of pirtobrutinib with rifampin (strong CYP3A inducer) decreased the AUC of pirtobrutinib by 71%.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Moderate CYP3A Inducers:</content> Efavirenz and bosentan (moderate CYP3A inducers) are predicted to decrease the AUC of pirtobrutinib by 49% and 27%, respectively.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Gastric Reducing Agents:</content> No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with omeprazole (a proton pump inhibitor).
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">P-glycoprotein (P-gp) inhibitors:</content> No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with itraconazole (P-gp inhibitor).
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">CYP3A Substrates:</content> Pirtobrutinib increased the AUC and C<sub>max</sub> of orally administered midazolam (sensitive CYP3A substrate) by 70% and 58%, respectively. Pirtobrutinib did not have a clinically meaningful effect on the exposure of intravenously administered midazolam.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">CYP2C8 Substrates:</content> Pirtobrutinib increased the AUC and C<sub>max</sub> of repaglinide (sensitive CYP2C8 substrate) by 130% and 98%, respectively.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">CYP2C19 Substrates:</content> Pirtobrutinib increased the AUC and C<sub>max</sub> of omeprazole (sensitive CYP2C19 substrate) by 56% and 49%, respectively.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">P-gp Substrates:</content> A single 200 mg dose of pirtobrutinib increased the AUC and C<sub>max</sub> of digoxin (sensitive P-gp substrate) by 17% and 51%, respectively. Multiple doses of pirtobrutinib (200 mg daily) further increased the AUC and C<sub>max</sub> of digoxin (sensitive P-gp substrate) up to 35% and 55%, respectively.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">BCRP Substrates:</content> Multiple doses of pirtobrutinib (200 mg daily) increased the AUC and C<sub>max</sub> of rosuvastatin (sensitive BCRP substrate) by 140% and 146%, respectively.
</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">CYP1A2 and CYP2C9 Substrates:</content> Pirtobrutinib did not have a clinically meaningful effect on the exposures of caffeine (sensitive CYP1A2 substrate) or S-warfarin (moderate sensitive CYP2C9 substrate).
</paragraph>
                                 </text>
                                 <effectiveTime value="20230127"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s59">
                                 <id root="645a201d-fceb-450d-bc63-3a7eb7a4b38c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Studies</content>
                                    </paragraph>
                                    <paragraph>Cytochrome P450 (CYP) Enzymes: Pirtobrutinib inhibits CYP2C8, CYP2C9, CYP3A, CYP1A2, CYP2B6, CYP2C19, and CYP2D6. Pirtobrutinib induces CYP3A4, CYP3A5, CYP2B6, and CYP2C19.
</paragraph>
                                    <paragraph>Transporter Systems: Pirtobrutinib inhibits P-gp and BCRP, but not OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K.  Pirtobrutinib is not a substrate of the hepatic transporters. Pirtobrutinib is a substrate of P-gp and BCRP, but not OCT1, OATP1B1, OATP1B3, or BSEP.
</paragraph>
                                 </text>
                                 <effectiveTime value="20230127"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s60">
               <id root="8d5f13ad-cbae-4bdb-8f2b-a02ad50db8d4"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20230127"/>
               <component>
                  <section ID="s61">
                     <id root="725130fb-f034-480c-bff7-a94299874a26"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, mutagenesis, impairment of fertility
</title>
                     <text>
                        <paragraph>Carcinogenicity studies have not been conducted with pirtobrutinib.
</paragraph>
                        <paragraph>Pirtobrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay. Pirtobrutinib was aneugenic in <content styleCode="italics">in vitro</content> micronucleus assays using human peripheral blood lymphocytes. Pirtobrutinib was not genotoxic in an <content styleCode="italics">in vivo</content> rat bone marrow micronucleus assay at doses up to 2000 mg/kg.
</paragraph>
                        <paragraph>Studies to assess the effects of pirtobrutinib on fertility have not been conducted. In repeat-dose toxicity studies of up to 3-months duration conducted with pirtobrutinib in rats and dogs, no effects on male or female reproductive organs were identified.
</paragraph>
                     </text>
                     <effectiveTime value="20230127"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s62">
               <id root="5c97019f-1195-4e3d-919d-e023258b01d0"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <effectiveTime value="20231201"/>
               <component>
                  <section ID="s63">
                     <id root="ddffb94a-1e0e-4dcc-948e-8dacb5ce5e77"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Mantle Cell Lymphoma
</title>
                     <text>
                        <paragraph>The efficacy of JAYPIRCA in patients with MCL was evaluated in BRUIN [NCT03740529], an open-label, international, multicohort, single-arm study of JAYPIRCA as monotherapy. Efficacy was based on 120 patients with MCL treated with JAYPIRCA who were previously treated with a BTK inhibitor. JAYPIRCA was given orally at a dose of 200 mg once daily and was continued until disease progression or unacceptable toxicity. Patients with active central nervous system lymphoma or allogeneic hematopoietic stem cell transplantation (HSCT) or CAR-T cell therapy within 60 days were excluded.
</paragraph>
                        <paragraph>The median age was 71 years (range: 46 to 88 years); 79% were male; 78% were White, 14% Asian, 1.7% Black or African American. Seventy-eight percent of patients had the classic/leukemic variant of MCL, 12% had pleomorphic MCL, and 11% had blastoid MCL. The simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) score was low in 15%, intermediate in 59%, and high in 26% of patients. Patients received a median number of 3 prior lines of therapy (range: 1 to 9) with 93% having received 2 or more prior lines. All received 1 or more prior lines of therapy containing a BTK inhibitor; other prior therapies included chemoimmunotherapy in 88%, HSCT in 20%, lenalidomide in 18%, and CAR-T therapy in 9%. The most common prior BTK inhibitors received were ibrutinib (67%), acalabrutinib (30%), and zanubrutinib (8%). Patients may have received more than one prior BTK inhibitor; 83% of patients discontinued the last BTK inhibitor for refractory or progressive disease, 10% discontinued for toxicity, and 5% discontinued for other reasons.
</paragraph>
                        <paragraph>Efficacy was based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2014 Lugano criteria. Efficacy results are shown in <linkHtml href="#t6">Table 6</linkHtml>. Additionally, the Kaplan-Meier estimate for the DOR rate at 6 months was 65.3% (95% CI: 49.8, 77.1).
</paragraph>
                        <table ID="t6" width="100%">
                           <caption>Table 6: Efficacy Results per IRC in Patients with MCL Previously Treated with a BTK Inhibitor
</caption>
                           <col width="47.400%" align="left"/>
                           <col width="52.600%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="footnote">CI, confidence interval; CR, complete response; DOR, duration of response; PR, partial response; NE, not estimable.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> PET-CT scans were utilized in response assessments (in 41% of patients), with the remainder being assessed by CT scans only.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> ORR using CT scan-based assessments in all patients was 48% (95% CI: 38, 57) and CR rate was 13%.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>c</sup> Based on Kaplan-Meier estimation. Estimated median follow-up was 7.3 months.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Outcome</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">JAYPIRCA 200 mg once daily</content>
                                    <br/>
                                    <content styleCode="bold">(N = 120)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Overall Response Rate
</content>
                                    <content styleCode="bold">
                                       <sup>a,b</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Â  Â  Â ORR, n
</td>
                                 <td align="center" valign="top" styleCode="Rrule">60 (50%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Â  Â  Â  (95% CI, %)
</td>
                                 <td align="center" valign="top" styleCode="Rrule">41, 59
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">CR, n
</td>
                                 <td align="center" valign="top" styleCode="Rrule">15 (13%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">PR, n
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">45 (38%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Time to Response</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Median (range), months
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.8 (0.8, 4.2)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Duration of Response
</content>
                                    <content styleCode="bold">
                                       <sup>c</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Â  Â  Â Number censored, n
</td>
                                 <td align="center" valign="top" styleCode="Rrule">36
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Â  Â  Â Median DOR, months (95% CI)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">8.3 (5.7, NE)
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20231201"/>
                  </section>
               </component>
               <component>
                  <section ID="s64">
                     <id root="a54d2e2b-f509-4bda-a050-500aeed7e71a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
</title>
                     <text>
                        <paragraph>The efficacy of JAYPIRCA in patients with CLL/SLL was evaluated in BRUIN [NCT03740529], an open-label, international, single-arm, multicohort study of JAYPIRCA as monotherapy. Efficacy was based on 108 patients with CLL/SLL treated with JAYPIRCA who were previously treated with at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. JAYPIRCA was given orally at a dose of 200 mg once daily and was continued until disease progression or unacceptable toxicity. The trial required a platelet count â¥ 50 x 10<sup>9</sup>/L, absolute neutrophil count â¥ 0.75 x 10<sup>9</sup>/L, hepatic transaminases â¤ 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with significant cardiovascular disease, major bleeding, uncontrolled or symptomatic arrhythmias, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor. Patients with active central nervous system (CNS) involvement by lymphoma or allogeneic hematopoietic stem cell transplantation (HSCT) within 60 days were excluded.
</paragraph>
                        <paragraph>The median age was 68 years (range: 41 to 88 years); 69% were male; 89% were White, 4.6% Black or African American, 1.9% Asian and 1.9% were Hispanic or Latino. Baseline ECOG performance status was 0 or 1 in 91% of patients and 48% of patients had Rai stage III or IV disease. Among those patients with central testing available, 42% (37 of 88 patients) had a C481 BTK mutation, 54% (43 of 79 patients) had 17p deletion and/or TP53 mutation, 93% (77 of 83 patients) had unmutated IGHV, and 22% (16 of 72 patients) had 11q deletion. Patients received a median number of 5 prior lines of therapy (range: 2 to 11). The most common prior BTK inhibitors received were ibrutinib (97%), acalabrutinib (9%), and zanubrutinib (0.9%). Seventy-seven percent of patients discontinued the last BTK inhibitor for refractory or progressive disease, 13% discontinued for toxicity, and 10% discontinued for other reasons.
</paragraph>
                        <paragraph>Efficacy was established based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2018 iwCLL criteria. Efficacy results are shown in <linkHtml href="#t7">Table 7</linkHtml>. The median time to response was 3.7 months (range: 1.7, 27.9 months).
</paragraph>
                        <table ID="t7" width="100%">
                           <caption>Table 7: Efficacy Results per IRC in Patients with CLL/SLL Previously Treated with a BTK Inhibitor and a BCL-2 inhibitor
</caption>
                           <col width="47.350%" align="left"/>
                           <col width="52.650%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="footnote">CI, confidence interval; PR, partial response.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> Based on Kaplan-Meier estimation. Estimated median follow-up was 15.7 months.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Outcome</content>
                                 </td>
                                 <td align="center" valign="bottom" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">JAYPIRCA 200 mg once daily</content>
                                    <br/>
                                    <content styleCode="bold">(N = 108)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Overall Response Rate</content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">ORR, n
</td>
                                 <td align="center" valign="top" styleCode="Rrule">78 (72%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">Â  Â  Â  (95% CI, %)
</td>
                                 <td align="center" valign="top" styleCode="Rrule">63, 80
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">PR, n
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">78 (72%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Duration of Response
</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Median DOR, months (95% CI)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">12.2 (9.3, 14.7)
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20231201"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s65">
               <id root="cd13d700-b132-42ad-af46-d4460bd241a5"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>JAYPIRCA tablets are supplied as follows:
</paragraph>
                  <table width="100%">
                     <col width="21.125%" align="left"/>
                     <col width="24.075%" align="left"/>
                     <col width="33.675%" align="left"/>
                     <col width="21.125%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Tablet Strength</content>
                           </td>
                           <td align="left" valign="bottom" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Description</content>
                           </td>
                           <td align="left" valign="bottom" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Package Configuration</content>
                           </td>
                           <td align="left" valign="bottom" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">NDC Number</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">50 mg
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Blue, film coated, arc-triangle shaped tablets debossed with âLilly 50â on one side and â6902â on the other side.
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Bottle with child-resistant closure.<br/>Each bottle contains 30 tablets.
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">0002-6902-30
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">100 mg
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Blue, film coated, round tablets debossed with âLilly 100â on one side and â7026â on the other side.
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">Bottle with child-resistant closure.<br/>Each bottle contains 60 tablets.
</td>
                           <td align="left" valign="top" styleCode="Botrule Rrule">0002-7026-60
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store JAYPIRCA tablets at room temperature 20Â°C to 25Â°C (68Â°F to 77Â°F); excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F) ([see USP Controlled Room Temperature]).
</paragraph>
               </text>
               <effectiveTime value="20231201"/>
            </section>
         </component>
         <component>
            <section ID="s67">
               <id root="88c18bf8-8368-4deb-826e-348a335c8cb6"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Infections</content>
                  </paragraph>
                  <paragraph>Advise patients that JAYPIRCA can cause serious infections that may be fatal. Advise patients to report any signs or symptoms of infection (e.g., fever, chills, weakness) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hemorrhage</content>
                  </paragraph>
                  <paragraph>Inform patients to report signs or symptoms of bleeding. Inform patients that JAYPIRCA may need to be interrupted for major surgeries <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.2</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cytopenias</content>
                  </paragraph>
                  <paragraph>Advise patients of the need for periodic monitoring of blood counts during treatment with JAYPIRCA <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.3</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cardiac Arrhythmias</content>
                  </paragraph>
                  <paragraph>Counsel patients to report any signs of palpitations, dizziness, fainting, chest discomfort, and shortness of breath <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s15">5.4</linkHtml>
                     </content>)<content styleCode="italics">]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Second Primary Malignancies</content>
                  </paragraph>
                  <paragraph>Inform patients that other malignancies have been reported in patients who have been treated with JAYPIRCA, including skin cancer and other solid tumors. Advise patients to use sun protection and to have monitoring for development of other cancers <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.5</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity, Including Drug-Induced Liver Injury</content>
                  </paragraph>
                  <paragraph>Inform patients that liver problems, including severe, life-threatening, or fatal hepatitis, drug-induced liver injury and abnormalities in liver tests, may develop during JAYPIRCA treatment. Advise patients to contact their healthcare provider immediately if they experience abdominal discomfort, dark urine, or jaundice <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16a">5.6</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.7</linkHtml>)</content>, <content styleCode="italics">Use in Specific Populations (<linkHtml href="#s29">8.1</linkHtml>, <linkHtml href="#s35">8.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s35">8.3</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise women not to breastfeed during treatment with JAYPIRCA and for one week after the last dose <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s33">8.2</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration</content>
                  </paragraph>
                  <paragraph>Inform patients to take JAYPIRCA orally once daily at approximately the same time each day with or without food and how to make up a missed dose. Advise patients to swallow tablets whole with water. Advise patients not to cut, crush, or chew tablets <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s4">2.1</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA</content>
                  </paragraph>
                  <paragraph>Copyright Â© 2023, 2024, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>JAY-0004-USPI-20240604
</paragraph>
               </text>
               <effectiveTime value="20240604"/>
            </section>
         </component>
         <component>
            <section ID="s68">
               <id root="d0a5d3c3-ffd9-4295-84e6-6eb599dd412b"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="33.333%" align="left"/>
                     <col width="50.867%" align="left"/>
                     <col width="15.800%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <paragraph styleCode="footnote">This Patient Information has been approved by the U.S. Food and Drug Administration. 
</paragraph>
                           </td>
                           <td align="left" valign="top">
                              <paragraph styleCode="footnote">Revised: 06/2024
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold">JAYPIRCA<sup>Â®</sup> (JAY-PIHR-KAA)</content>
                              <br/>
                              <content styleCode="bold">pirtobrutinib</content>
                              <br/>
                              <content styleCode="bold">tablets</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is JAYPIRCA?</content>
                              <br/>JAYPIRCA is a prescription medicine used to treat adults with:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment and who have already received at least 2 treatments for their cancer, including a Bruton tyrosine kinase (BTK) inhibitor medicine.
</item>
                                 <item>chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received at least 2 treatments for their cancer, including a BTK inhibitor medicine and a B-cell lymphoma 2 (BCL-2) inhibitor medicine.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">It is not known if JAYPIRCA is safe and effective in children.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before taking JAYPIRCA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have an infection or have been advised that you are at increased risk of infection
</item>
                                 <item>have had recent surgery or plan to have surgery. Your healthcare provider may stop JAYPIRCA for any planned medical, surgical, or dental procedure.
</item>
                                 <item>have bleeding problems or are taking a blood thinner medicine
</item>
                                 <item>have or had heart rhythm problems
</item>
                                 <item>have high blood pressure
</item>
                                 <item>have a history of other cancers including skin cancer
</item>
                                 <item>have kidney problems
</item>
                                 <item>have liver problems</item>
                                 <item>are pregnant or plan to become pregnant. JAYPIRCA can harm your unborn baby.<paragraph>
                                       <content styleCode="bold">Females who are able to become pregnant:</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider will do a pregnancy test before starting treatment with JAYPIRCA.
</item>
                                       <item>You should use effective birth control (contraception) during treatment with JAYPIRCA and for 1 week after your last dose of JAYPIRCA.
</item>
                                       <item>Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with JAYPIRCA.
</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if JAYPIRCA passes into your breast milk. Do not breastfeed during treatment with JAYPIRCA and for 1 week after your last dose of JAYPIRCA.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking JAYPIRCA with certain other medicines may affect how JAYPIRCA or the other medicines work and can cause side effects.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">How should I take JAYPIRCA?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take JAYPIRCA exactly as your healthcare provider tells you.
</item>
                                 <item>Do not change your dose or stop taking JAYPIRCA unless your healthcare provider tells you to do so.
</item>
                                 <item>Take JAYPIRCA tablets 1 time each day at about the same time each day.
</item>
                                 <item>Take JAYPIRCA with or without food.
</item>
                                 <item>Swallow JAYPIRCA tablets whole with water. Do not cut, crush, or chew the tablets.
</item>
                                 <item>If you miss a dose of JAYPIRCA, take it as soon as you remember on the same day. If it has been more than 12Â hours from the time you usually take JAYPIRCA, skip the missed dose, and take your next dose on the next day at your usual time.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of JAYPIRCA?</content>
                              <br/>
                              <content styleCode="bold">JAYPIRCA can cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Infections</content> can happen during treatment with JAYPIRCA. These infections can be serious and may lead to death. Your healthcare provider may prescribe vaccines and certain medicines if you have an increased risk of getting infections. Tell your healthcare provider right away if you develop fever, chills, weakness, flu-like symptoms, or any other signs of infection during treatment with JAYPIRCA.
</item>
                                 <item>
                                    <content styleCode="bold">Bleeding problems (hemorrhage)</content> can happen during treatment with JAYPIRCA and can be serious and may lead to death. Your risk of severe bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you develop any signs or symptoms of bleeding, including:						<table width="100%" styleCode="Noautorules">
                                       <col width="55.100%" align="left"/>
                                       <col width="44.900%" align="left"/>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>blood in your stools or black stools (looks like tar)
</item>
                                                   <item>pink or brown urine
</item>
                                                   <item>unexpected bleeding, or bleeding that is severe or you cannot control
</item>
                                                   <item>vomit blood or vomit blood that looks like coffee grinds
</item>
                                                   <item>cough up blood or blood clots
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>increased bruising
</item>
                                                   <item>dizziness
</item>
                                                   <item>weakness
</item>
                                                   <item>confusion
</item>
                                                   <item>changes in your speech
</item>
                                                   <item>headache that lasts a long time
</item>
                                                </list>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Decrease in blood cell counts.</content> Decrease in blood cell counts (white blood cells, platelets, and red blood cells) are common with JAYPIRCA, but can also be severe. This may increase your risk of infection, bleeding, and anemia. Your healthcare provider should do blood tests to check your blood counts regularly during treatment with JAYPIRCA.
</item>
                                 <item>
                                    <content styleCode="bold">Heart rhythm problems.</content> Heart rhythm problems including atrial fibrillation and atrial flutter have happened in people treated with JAYPIRCA. Your risk for heart rhythm problems may be increased if you have high blood pressure or have had heart rhythm problems in the past. Tell your healthcare provider if you develop any of the following signs or symptoms:						<table width="100%" styleCode="Noautorules">
                                       <col width="46.800%" align="left"/>
                                       <col width="53.200%" align="left"/>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>fast or irregular heartbeat (palpitations)
</item>
                                                   <item>dizziness
</item>
                                                   <item>fainting
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>chest discomfort
</item>
                                                   <item>shortness of breath
</item>
                                                </list>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Second primary cancers.</content> New cancers have happened in people during treatment with JAYPIRCA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with JAYPIRCA. Use sun protection when you are outside in sunlight.
</item>
                                 <item>
                                    <content styleCode="bold">Liver Problems.</content> Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with JAYPIRCA. Your healthcare provider will do blood tests to check your liver before and during treatment with JAYPIRCA. Tell your healthcare provider or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">Your healthcare provider may decrease your dose, temporarily stop, or permanently stop treatment with JAYPIRCA if you develop severe side effects.<br/>
                              <content styleCode="bold">The most common side effects of JAYPIRCA include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>tiredness
</item>
                                 <item>muscle, joint, and bone pain
</item>
                                 <item>diarrhea
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>COVID-19
</item>
                                 <item>bruising
</item>
                                 <item>cough
</item>
                              </list>
                           </td>
                           <td align="left" valign="top" styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">These are not all the possible side effects of JAYPIRCA.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store JAYPIRCA?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store JAYPIRCA at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).
</item>
                                 <item>JAYPIRCA comes in a bottle with a child-resistant cap.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Keep JAYPIRCA and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of JAYPIRCA.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use JAYPIRCA for a condition for which it was not prescribed. Do not give JAYPIRCA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about JAYPIRCA that is written for health professionals.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in JAYPIRCA?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> pirtobrutinib<br/>
                              <content styleCode="bold">Inactive ingredients:</content> croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and silicon dioxide. The tablet film coating contains FD&amp;C Blue #2, hypromellose, titanium dioxide, and triacetin.<br/>
                              <br/>
                              <content styleCode="bold">Marketed by Lilly USA, LLC, Indianapolis, IN 46285, USA</content>
                              <br/>JAYPIRCA is a registered trademark of Eli Lilly and Company.<br/>Copyright Â© 2023, 2024, Eli Lilly and Company. All rights reserved.<br/> JAY-0004-PPI-20240604 <br/>
                              <br/>For more information, go to www.jaypirca.com or call 1-800-LillyRx (1-800-545-5979).
</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20240604"/>
            </section>
         </component>
         <component>
            <section ID="s69">
               <id root="e02db351-04c9-4804-94e7-3fd419daebca"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL â JAYPIRCA 50 mg Tablets, 30 count bottle</content>
                  </paragraph>
                  <paragraph>NDC 0002-6902-30
</paragraph>
                  <paragraph>30 tablets Â  Â  Â  Â  Â Rx only
</paragraph>
                  <paragraph>Jaypirca<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(pirtobrutinib) <br/> tablets
</paragraph>
                  <paragraph>50 mg
</paragraph>
                  <paragraph>Each tablet contains 50 mg pirtobrutinib
</paragraph>
                  <paragraph>www.jaypirca.com
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f02" referencedObject="mm02"/>
               </text>
               <effectiveTime value="20241113"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>PACKAGE LABEL â JAYPIRCA 50 mg Tablets, 30 count bottle
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jaypirca-50mg-bottle-076-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s70">
               <id root="45d1363e-1a1f-4bea-bff2-d88f03d0a271"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL â JAYPIRCA 100 mg Tablets, 60 count bottle</content>
                  </paragraph>
                  <paragraph>NDC 0002-7026-60
</paragraph>
                  <paragraph>60 tablets Â  Â  Â  Â  Â Rx only
</paragraph>
                  <paragraph>Jaypirca<sup>Â®</sup>
                  </paragraph>
                  <paragraph>(pirtobrutinib)
 <br/> tablets
</paragraph>
                  <paragraph>100 mg
</paragraph>
                  <paragraph>Each tablet contains 100 mg pirtobrutinib
</paragraph>
                  <paragraph>www.jaypirca.com
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f03" referencedObject="mm03"/>
               </text>
               <effectiveTime value="20241113"/>
               <component>
                  <observationMedia ID="mm03">
                     <text>PACKAGE LABEL â JAYPIRCA 100 mg Tablets, 30 count bottle
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="jaypirca-100mg-bottle-074-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>